Clinical Scorecard: Mechanisms and Therapeutic Promise of Electroacupuncture for Non-Alcoholic Fatty Liver Disease

At a Glance

Key Highlights

• NAFLD is the most prevalent chronic liver disorder globally, affecting approximately one-third of adults.
• Electroacupuncture shows promise as an adjunctive intervention for improving hepatic steatosis and metabolic parameters.
• No pharmacological therapies are currently approved specifically for NAFLD/MASLD.
• Lifestyle interventions remain the cornerstone of therapy, with a focus on weight loss and dietary modifications.
• Emerging pharmacological agents and novel therapeutic targets are under investigation, including resmetirom, the first FDA-approved agent for MASH.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of MASLD should consider the spectrum from simple steatosis to steatohepatitis and cirrhosis.

Management

• Lifestyle modifications including dietary changes and weight loss are essential.
• Investigate pharmacological options such as insulin sensitizers, FDA-approved agents like resmetirom, and other emerging therapies.

Monitoring & Follow-up

• Regular assessment of liver function and metabolic parameters is recommended.

Risks

• Long-term adherence to lifestyle changes is often limited; inconsistent therapeutic outcomes for many agents.

Patient & Prescribing Data

Adults with NAFLD/MASLD, particularly those with metabolic dysfunction.

Electroacupuncture may provide a low-risk adjunctive treatment option with minimal side effects.

Clinical Best Practices

• Encourage sustained weight loss of 7%-10% to improve liver health.
• Consider electroacupuncture as a complementary therapy in managing NAFLD/MASLD.
• Emphasize the importance of regular monitoring of liver function and metabolic parameters.

References

• Mechanisms and Therapeutic Promise of Electroacupuncture for Non-Alcoholic Fatty Liver Disease